A corporate venture arm of a diversified business based in Asia is focused on three primary sectors, and one of them includes healthcare. The team has offices in key hub cities in USA, and the fund has an evergreen structure looking to allocate between $1-3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An angel fund based in Canada is very active in their portfolio companies’ development, and is looking to add value through augmenting management, strategy, operations, etc. The firm makes initial investments in the range of $250K – $750K, and is flexible with structure, using both convertible loans as well as straight equity. The group is focused on seed and Series A opportunities and typically looks to lead these deals, but may also invest with a syndicate of other angels and VCs. Although the firm is exclusively focused on Canadian companies, the group has deep connections with medtech and institutional partners across North America and Israel.

The firm is focused on the medical technology and diagnostics sectors and is generally agnostic to technology type, but has specific interest and expertise in the imaging space. The group also favors surgical devices, minimally invasive tools and in-vitro diagnostics. The group only evaluates class I devices and those with 510(k) regulatory pathways, and does not invest in devices/diagnostics that require a PMA. The firm will invest at the earliest stages of development.

The firm is open to working with all entrepreneurs and will invest in companies with incomplete management teams, working to fill in and build out key management positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment group founded by Chinese medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel, pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China.

The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses.

The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage investment and development firm located in the USA has more than $300 million in assets and operates under an evergreen structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US-based VC fund founded in 2016 and based in is investing out of a $261M fund. Within the life sciences, the firm is interested in therapeutics, medical devices, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical devices, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning-based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.